Advances in the Development of Ubiquitination Pathway Targets for the Treatment of Tumours

In recent years, oncology research has made great progress, but malignant tumours still become a great threat to human health, and many cancer treatments as well as targeted drug therapy for cancer have been developed, which can largely inhibit the development of cancer cells and even cure cancer. The research related to ubiquitination in cancer therapy research is also increasing year by year. Ubiquitination plays a very important role in protein localisation, metabolism, function, regulation and degradation. This also means that ubiquitination has a very important role in the treatment of tumour-related targets. This paper analyses the control of the ubiquitination pathway through the use of specific small molecule inhibitors. Such small molecule inhibitors inhibit a range of deubiquitinating enzymes so that negatively regulated proteins in the target molecule can be normally ubiquitinated and degraded, and t-cells can normally recognise and suppress tumourigenesis. Research into the effects of small molecule inhibitors on the ubiquitination pathway is making great progress today, which will be of great help in the future treatment of tumours. At the same time, the synergistic delivery of this approach with existing targeted drugs is also an important direction for future development that needs to be investigated.